Protection is Never Premature_Maternal COVID-19 Infection and Adverse Perinatal Outcomes

Protection is Never Premature: Maternal COVID-19 Infection is Associated with Adverse Perinatal Outcomes

/0 Comments/in , , , /by

Pregnancy can be divided into three trimesters, corresponding to different stages of foetal development — the first trimester (Weeks 0 to 13+6) is characterised by foetal organ growth including neurodevelopment and craniofacial development; developed organs gain functionality during the second trimester (Weeks 14 to 26+6) and the foetus grows further and prepares for viability at the third trimester (Weeks 27 to 40+6).

Read more
Should your child receive covid-19 vaccination? Risk-benefit analyses in infants, children, and adolescents

Should your child receive covid-19 vaccination? Risk-benefit analyses in infants, children, and adolescents

/Enter your password to view comments./in , , , /by

There is no excerpt because this is a protected post.

Read more

Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

/0 Comments/in , , , /by

On 20 December 2018, the FDA approved the asparagine specific enzyme calaspargase pegol-mknl (Asparlas®, Servier) as a component of multi-agent chemotherapeutic regimens for the treatment of paediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukaemia (ALL).

Read more

Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

/0 Comments/in , , , /by

On 21 December 2018, the FDA approved the CD123-directed cytotoxin tagraxofusp-erzs (Elzonris™, Stemline Therapeutics), for the treatment of adult and paediatric patients of 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Read more